Literature DB >> 17000466

Neurochemical and behavioural characterisation of alkoxyamphetamine derivatives in rats.

Cesar A Romero1, Diego A Bustamante, Gerald Zapata-Torres, Michel Goiny, Bruce Cassels, Mario Herrera-Marschitz.   

Abstract

The clinical utility of amphetamine and amphetamine analogues has been jeopardized by a number of side effects and toxicity, partly due to complex mechanisms of action. While some of the analogues have been individually characterised, there is still need for comparative studies, in particularly on their efficacy to release dopamine and 5-hydroxytryptamine, further enlightening some of the synaptic mechanisms conveying their actions. Thus, we have compared four alkoxyamphetamine derivatives, i.e., p-methoxyamphetamine; p-methoxymethamphetamine; methylenedioxyamphetamine, methylenedioxymethamphetamine, using methamphetamine, and D-amphetamine, as reference substances, on rotational behaviour and releasing mechanisms studied with in vivo microdialysis in rats. All alkoxylated-derivatives produced a long-lasting rotational behaviour at 10 mg/kg s.c., but the reference substances produced a strong rotation already at 2 mg/kg s.c. in 6-hydroxydopamine-lesioned rats. At the concentration of 100 micromolar, the alkoxylated-derivatives were equipotent to evoke dopamine and 5-hydroxytryptamine release in rat neostriatum, while D-amphetamine and methamphetamine were more efficient on dopamine release. Pre-treatment with methamphetamine or the alkoxylated-derivatives produced a remarkable decrease of the effect of K+ -depolarisation on both dopamine and 5-hydroxytryptamine release. The insertion of a methoxy or a methylenedioxy group on the benzene ring of D-amphetamine or methamphetamine, or N-methylation of the D-amphetamine molecule alters the selectivity of the compounds. The efficacy of the alkoxylated-derivatives on dopamine and 5-hydroxytryptamine release was similar, but stimulated less dopamine release and produced less rotational behaviour than D-amphetamine and methamphetamine. The lower efficacy of K+ -depolarisation following pre-treatments with the derivatives suggests an impairment of releasable monoamine stores. The present observations can enlighten the mechanisms of action of drugs showing a high risk for abuse among young populations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17000466     DOI: 10.1007/bf03033330

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  61 in total

1.  Striatal and cortical NMDA receptors are altered by a neurotoxic regimen of methamphetamine.

Authors:  A J Eisch; S J O'Dell; J F Marshall
Journal:  Synapse       Date:  1996-03       Impact factor: 2.562

2.  Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines.

Authors:  K B Burrows; W L Nixdorf; B K Yamamoto
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

3.  Methamphetamine rapidly decreases vesicular dopamine uptake.

Authors:  J M Brown; G R Hanson; A E Fleckenstein
Journal:  J Neurochem       Date:  2000-05       Impact factor: 5.372

4.  Effect of acute and chronic methamphetamine treatment on tyrosine hydroxylase activity in brain and adrenal medulla.

Authors:  H C Fibiger; E G Mogeer
Journal:  Eur J Pharmacol       Date:  1971-10       Impact factor: 4.432

Review 5.  Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens.

Authors:  D E Nichols
Journal:  J Psychoactive Drugs       Date:  1986 Oct-Dec

Review 6.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

Authors:  H Kalant
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

7.  Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate.

Authors:  W L Nixdorf; K B Burrows; G A Gudelsky; B K Yamamoto
Journal:  J Neurochem       Date:  2001-04       Impact factor: 5.372

8.  Analgesic and behavioral effects of amphetamine enantiomers, p-methoxyamphetamine and n-alkyl-p-methoxyamphetamine derivatives.

Authors:  Diego Bustamante; Gabriela Díaz-Véliz; Carlos Paeile; Gerald Zapata-Torres; Bruce K Cassels
Journal:  Pharmacol Biochem Behav       Date:  2004-10       Impact factor: 3.533

9.  Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine.

Authors:  K Frey; M Kilbourn; T Robinson
Journal:  Eur J Pharmacol       Date:  1997-09-10       Impact factor: 4.432

10.  The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain.

Authors:  D M Stone; D C Stahl; G R Hanson; J W Gibb
Journal:  Eur J Pharmacol       Date:  1986-08-22       Impact factor: 4.432

View more
  2 in total

Review 1.  Methamphetamine toxicity and its implications during HIV-1 infection.

Authors:  Peter S Silverstein; Ankit Shah; Raeesa Gupte; Xun Liu; Robert W Piepho; Santosh Kumar; Anil Kumar
Journal:  J Neurovirol       Date:  2011-07-23       Impact factor: 2.643

Review 2.  Exploring neurocircuitries of the basal ganglia by intracerebral administration of selective neurotoxins.

Authors:  Mario Herrera-Marschitz; Diego Bustamante; Paola Morales; Michel Goiny
Journal:  Neurotox Res       Date:  2007-04       Impact factor: 3.911

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.